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Abstract Whether all inflammatory agents activate nuclear
transcription factors NF-UB and activated protein-1 (AP-1)
through the same mechanism is not known. We examined the
effect of the phosphatidylinositol-3-kinase (PI-3K) inhibitor
wortmannin on the activation of NF-UB and AP-1 by different
inflammatory agents. Wortmannin blocked NF-UB and AP-1
activation by lipopolysaccharide and phorbol ester but had
minimal effect on activation by hydrogen peroxide, ceramide,
okadaic acid and tumor necrosis factor. Inhibition of NF-UB
correlated with abrogation of the degradation of IUBK and of
NF-UB-dependent reporter gene transcription. Thus, the mechan-
ism of NF-UB and AP-1 activation by lipopolysaccharide and
phorbol ester involves PI-3K.
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1. Introduction
In£ammation is an essential host-defense mechanism that is
induced in response to a wide variety of exogenous and en-
dogenous stimuli. These include radiation, lipopolysaccharide
(LPS), products of gram-negative bacteria, cytokines (such as
tumor necrosis factor (TNF) and interleukin-1 (IL-1)), ceram-
ide, H2O2, phorbol ester (PMA), hyperoxia/hypoxia, chemo-
therapeutic agents and okadaic acid (OA). When cells are
exposed to in£ammatory agents, a number of genes are acti-
vated, including those encoding cell surface adhesion proteins,
cyclooxygenases, lipooxygenases, in£ammatory cytokines and
their receptors, components of the major histocompatibility
complex and metalloproteases. The promoter region of most
of these genes contains binding sites for nuclear transcription
factor-UB (NF-UB). Activation of this factor leads to the ex-
pression of these in£ammatory genes. Most of the in£amma-
tory stimuli listed in fact activate NF-UB (for references see
[1]).
Under normal conditions, NF-UB is found in the cytoplasm
of all eukaryotic cells as a heterotrimer consisting of p50, p65
and an inhibitory subunit of NF-UB (IUBK). When cells are
exposed to in£ammatory agents, within minutes in most cases
IUBK undergoes phosphorylation, ubiquitination and degra-
dation, thus exposing the nuclear localization signals on p50
and p65, which in turn results in translocation of the p50^p65
heterodimer to the nucleus. This activated heterodimer then
binds to a unique decameric nucleotide sequence present in
the promoter of the in£ammatory genes, leading to gene ex-
pression.
Although the phosphorylation of IUBK at serines 32 and 36
is considered a critical step, the pathway that leads to it is
incompletely understood. Three di¡erent kinases, referred to
as NF-UB-inducing kinase, IKK-K, and IKK-L, that are in-
volved in the phosphorylation of IUBK have recently been
identi¢ed. However, it is not clear how these kinases are in-
terrelated and how they phosphorylate IUBK (for references
see [2]). These kinases are activated in response to TNF, but
whether they are activated in response to other in£ammatory
stimuli is also not clear nor is the kinase activation pathway.
Protein tyrosine kinases, protein tyrosine phosphatases, reac-
tive oxygen intermediates and ceramide have also been impli-
cated in this pathway [3^6].
Most agents that activate NF-UB also activate activated
protein-1 (AP-1), another transcription factor [7]. Like NF-
UB, AP-1 is also a heterodimer, consisting of c-Fos and c-Jun
proteins. The activation of AP-1 by in£ammatory stimuli in-
volves induction of c-fos synthesis and the phosphorylation of
both c-Fos and c-Jun [8].
By using wortmannin [9], which blocks the enzymatic activ-
ity of phosphatidylinositol-3-kinases (PI-3K), it has been
shown that PI-3K plays a role in AP-1 activation by epider-
mal growth factor, IL-1, and PMA [10^12]. CD28-mediated
AP-1 activation in T cells also requires PI-3K [13]. The role of
PI-3K in the activation of NF-UB is less clear. Recent reports
indicate that wortmannin has no e¡ect on CD28-mediated
NF-UB activation but that activated by IL-1 is blocked
[12,13], thus suggesting there is a di¡erence in the pathways.
Whether wortmannin a¡ects NF-UB and AP-1 activation in-
duced by other in£ammatory stimuli is not known.
In the present report, we investigated the e¡ects of wort-
mannin on the activation of AP-1 and NF-UB by TNF, LPS,
PMA, ceramide, H2O2 and OA. Our results indicate that
wortmannin blocks NF-UB and AP-1 activation induced by
LPS and PMA but not that activated by TNF, ceramide,
H2O2 or OA. NF-UB-dependent reporter gene expression
was also di¡erentially regulated thus suggesting that NF-UB
and AP-1 are activated by di¡erent pathways when exposed to
di¡erent agents.
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2. Materials and methods
2.1. Materials
Wortmannin, glycine, H7, PMA, LPS (Escherichia coli, 055:B5),
H2O2, OA, ceramide (C-2) and chloramphenicol were obtained from
Sigma (St. Louis, MO, USA). All other reagents were obtained as
previously described [6].
2.2. Cell lines
The cell lines U937 (human histiocytic lymphoma), Jurkat (human
T-cell), HeLa (human epithelial) and H4 (human glioma) were ob-
tained and cultured as described [6].
2.3. Assay for NF-kB and AP-1
Activated NF-UB and AP-1 were assayed following the method as
described [6,15]. A 45-mer double-stranded NF-UB oligonucleotide
from the HIV-LTR, 5P-TTGTTACAAGGGACTTTCCGCTG
GGGACTTTC CAGGGA GGCGT GG-3P (bold indicates NF-UB
binding sites) was used for NF-UB binding. To examine the speci¢city
of binding of NF-UB to the DNA, a double-stranded mutated oligo-
nucleotide, 5PTTGTTACAA CTCACTTTC CGCTGCTCACTTTC-
CAGGGAGG CGTGG-3P, was used.
To assay for AP-1 activation, the 32P-end-labeled AP-1 consensus
oligonucleotide 5P-CGCTTGA TGACTCA GCCGGAA-3P (bold in-
dicates AP-1 binding site) was used.
2.4. Western blot
After the NF-UB activation reaction described above, postnuclear
extracts were resolved on 8.5% Sodium dodecyl sulfate^polyacryl-
amide gels, electrotransferred and probed with a rabbit polyclonal
antibody against IUBK and p65 and detected by chemiluminescence
(ECL, Amersham) [16].
2.5. Transient transfection and chloramphenicol acetyltransferase
(CAT) assay
NF-UB-dependent gene expression was measured by a transient
transfection of U937 cells with -243RMICAT (wild) and -243RMI-
CAT-km (mutant) genes [14] for 6 h by the calcium phosphate meth-
od at 37‡C and then treated with wortmannin (10 nM) for 1 h before
stimulation with 0.1 and 1 Wg/ml of serum-activated (SA)-LPS or 10
and 25 ng/ml of PMA for 1 h. Thereafter, the cells were washed with
phosphate-bu¡ered saline and examined for CAT activity as described
[17].
3. Results
Whether PI-3K plays any role in the pathway leading to
activation of NF-UB and AP-1 was examined using wortman-
nin and a wide variety of NF-UB and AP-1 inducers. The time
of incubation and the concentration of wortmannin used in
our studies had no e¡ect on cell viability as determined by the
trypan blue dye uptake method (data not shown).
3.1. Wortmannin blocks NF-UB activated selectively by
PMA and SA-LPS
The results shown in Fig. 1A indicate that wortmannin
completely blocked the activation of NF-UB induced by SA-
LPS and PMA, had a partial e¡ect on activation by ceramide
and no e¡ect on activation by H2O2, OA and TNF. Thus
there must be a di¡erence in the pathways leading to NF-
UB activation induced by di¡erent agents.
To show that the retarded band visualized by electropho-
retic mobility shift assay (EMSA) in SA-LPS-treated cells was
indeed NF-UB, we incubated nuclear extracts from SA-LPS-
activated cells with antibody (Ab) to either p50 (NF-UBI) or
p65 (Rel A) subunits and then conducted EMSA. Antibodies
to either subunit of NF-UB retarded the mobility and shifted
the band to a higher molecular weight (Fig. 1B), thus suggest-
ing that the SA-LPS-activated complex consisted of p50 and
p65 subunits. Neither preimmune serum nor the irrelevant
antibodies anti-cRel and anti-cyclin DI had any e¡ect on
the mobility of NF-UB. In addition the results show that the
NF-UB band disappeared in the presence of excess (100-fold)
cold NF-UB probe, and an oligonucleotide with mutated NF-
UB site failed to bind to the NF-UB protein, thus all together
indicating the composition and speci¢city of binding of NF-
UB to the DNA.
3.2. Dose^response of inhibition by wortmannin of
NF-UB activation
To determine the minimum amount of wortmannin re-
quired to block LPS- and PMA-induced NF-UB activation,
U937 cells were preincubated for 1 h with di¡erent concen-
trations of wortmannin followed by treatment with SA-LPS
(100 ng/ml) or PMA (25 ng/ml) for 30 min at 37‡C and then
examined for NF-UB activation by EMSA. The results in Fig.
Fig. 1. A: E¡ect of wortmannin on di¡erent activators (PMA, SA-
LPS, H2O2, OA, ceramide and TNF) of NF-UB. U937 cells (2U106/
ml) were preincubated for 1 h at 37‡C with wortmannin (5 nM) fol-
lowed by PMA (25 ng/ml), SA-LPS (100 ng/ml), H2O2 (250 WM),
OA (500 nM), ceramide (10 WM) or TNF (0.1 nM) for 30 min and
then tested for NF-UB activation as described in Section 2. B: NF-
UB is composed of p50 and p65 subunits. Nuclear extracts from
TNF-treated cells were incubated with anti-p50, anti-p65, anti-c-Rel,
anti-cyclin D1, preimmune serum or unlabeled probe for 1 h at
room temperature and then analyzed for NF-UB by EMSA as de-
scribed. To determine the speci¢city, the oligo with mutated NF-UB
binding site was labeled and used for binding.
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2A indicate that 10 nM wortmannin inhibited almost 90% of
the SA-LPS-induced NF-UB activation. The same concentra-
tion of wortmannin had a more dramatic e¡ect on PMA-in-
duced NF-UB activation (Fig. 2B) reducing NF-UB activation
below basal levels.
3.3. Wortmannin inhibits SA-LPS- and PMA-dependent
degradation of IUBK
To determine whether the inhibitory action of wortmannin
was due to its e¡ect on IUBK degradation, the cells were pre-
treated with di¡erent concentrations of wortmannin for 1 h
and then stimulated with either SA-LPS or PMA for 15 min,
the cytoplasmic extracts were prepared and examined for lev-
els of IUBK by Western blot analysis. The IUBK was degraded
completely within 15 min by SA-LPS or PMA in untreated
U937 cells (data not shown). With increased concentrations of
wortmannin there was a decrease in the degradation of IUBK
induced by SA-LPS (Fig. 2C) or by PMA (Fig. 2D). A 50%
decrease with 0.5 nM and 100% protection at 5 nM of wort-
Fig. 2. E¡ect of di¡erent concentrations of wortmannin on induc-
tion of NF-UB by SA-LPS (A) and PMA (B). U937 cells (2U106/
ml), pretreated with di¡erent concentrations of wortmannin for 1 h
at 37‡C, were incubated with SA-LPS (A) or PMA (B) for 30 min
and then assayed for NF-UB by EMSA. C and D: E¡ect of wort-
mannin on degradation of IUBK U937 cells (2U106/ml), pretreated
with di¡erent concentrations of wortmannin for 1 h at 37‡C and in-
cubated with SA-LPS (C) or PMA (D) for 15 min and assayed for
IUBK in cytosolic fractions by Western blot analysis.
C
Fig. 3. E¡ect of wortmannin and H7 on activation of NF-UB in-
duced by SA-LPS (panel A) and PMA (panel B) in di¡erent cell
lines. Jurkat, HeLa and H4 cells (2U106/ml) were pretreated with
wortmannin (5 nM) and H7 (50 nM) for 1 h at 37‡C and then incu-
bated with 100 ng/ml SA-LPS (panel A) or 25 ng/ml PMA (panel
B) for 30 min. After these treatments nuclear extracts were prepared
and then assayed for NF-UB.
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mannin was observed in the case of SA-LPS stimulation (Fig.
2C). In the case of PMA, 1 nM wortmannin gave about 50%
protection and complete protection was observed at 5 nM
(Fig. 2D). Wortmannin by itself had no e¡ect on the consti-
tutive levels of IUBK. These results indicate that wortmannin
blocked NF-UB activation by blocking IUBK degradation.
3.4. Inhibition of NF-UB activation by wortmannin is not cell
type-speci¢c
All the e¡ects of wortmannin described so far were ob-
served in U937 cells. Since the NF-UB activation mechanism
has been shown to di¡er between epithelial and lymphoid cells
[18], we investigated whether wortmannin a¡ects NF-UB acti-
vation in T-cells (Jurkat) and epithelial (HeLa) and glioma
(H4) cells. Wortmannin inhibited NF-UB activation in all
cell types by both SA-LPS (Fig. 3A) and PMA (Fig. 3B). In
all cell types H7, a protein kinase C (PKC) inhibitor, blocked
both LPS- (Fig. 3A) and PMA-induced (Fig. 3B) NF-UB ac-
tivation. These results suggest that like PMA, LPS may also
activate NF-UB through induction of PKC.
3.5. Wortmannin represses NF-UB-CAT reporter gene
expression
We investigated whether wortmannin blocked NF-UB-de-
pendent gene expression. The promoter of the MDR gene
containing a NF-UB site linked to a CAT reporter gene was
used to transiently transfect the cells, the cells were pretreated
with wortmannin and then they were stimulated with SA-LPS
or PMA and assayed for CAT expression. As expected, an
almost seven-fold increase in CAT activity occurred upon
stimulation with 100 ng/ml concentration of SA-LPS (Fig.
4A). This activity was reduced by greater than 90% on pre-
treatment of cells with wortmannin for 1 h. About a six-fold
increase in CAT expression was observed in PMA-treated
cells and this increase was completely abolished by wortman-
nin (Fig. 4B). The transfection of cells with plasmids that had
a mutated NF-UB-binding site did not result in induction of
CAT activity by either SA-LPS or PMA, thus indicating that
this e¡ect was dependent on NF-UB. These results demon-
strate that wortmannin also blocked NF-UB-dependent gene
expression.
3.6. Wortmannin inhibits SA-LPS- and PMA-induced
AP-1 activation
Most of the agents that activate NF-UB also activate the
transcription factor AP-1 [7]. Therefore, we examined the ef-
fect of wortmannin on activation of AP-1 by PMA, SA-LPS,
H2O2, OA, ceramide and TNF. As shown in Fig. 5, all ¢ve
agents activated AP-1. However, only SA-LPS- and PMA-
induced AP-1 activation was blocked by wortmannin.
In U-937 cells, SA-LPS activated AP-1 in a dose-dependent
manner reaching its maximum of about seven-fold at a con-
centration of 100 ng/ml SA-LPS (Fig. 6A). PMA activated
AP-1 by seven-fold at 25 ng/ml dose (Fig. 6B). The minimum
concentration of wortmannin required to inhibit LPS- and
PMA-induced activation of AP-1 was found to be 5 nM, a
dose that suppressed activation induced by both SA-LPS (Fig.
6C) and PMA (Fig. 6D) by 90%. These results indicate that
wortmannin blocks not only NF-UB activation but also AP-1
activation induced by LPS and PMA.
Fig. 4. E¡ect of wortmannin on the NF-UB-dependent CAT report-
er gene expression induced by SA-LPS and PMA. Cells were transi-
ently transfected with MDR-NF-UB-CAT (-243RMICAT), both
wild (wt) and mutant (mut), treated with 5 nM wortmannin for 1 h,
exposed to 100 ng/ml SA-LPS (A) and 25 ng/ml PMA (B) for 1 h
and then assayed for CAT activity as described in Section 2. Results
are expressed as fold activity over the non-transfected control.
Fig. 5. E¡ect of wortmannin on di¡erent activators (PMA, SA-LPS,
H2O2, OA, ceramide and TNF) of AP-1. U937 cells (2U106/ml)
were pre-incubated for 1 h at 37‡C with wortmannin (5 nM) fol-
lowed by PMA (25 ng/ml), SA-LPS (100 ng/ml), H2O2 (250 WM),
OA (500 nM), ceramide (10 WM) or TNF (0.1 nM) for 30 min and
then tested for AP-1 activation as described in Section 2.
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4. Discussion
Our results show that wortmannin blocked NF-UB activa-
tion induced by LPS and by PMA, but had no signi¢cant
e¡ect on H2O2-, OA- or TNF-induced NF-UB activation. Cer-
amide-induced NF-UB activation was partially a¡ected. The
IUBK degradation needed for nuclear translocation of NF-UB
was completely blocked by the PI-3K inhibitor. This corre-
lated with NF-UB-dependent reporter gene expression. The
inhibitory e¡ect of wortmannin was not cell type-speci¢c.
The various steps that lead to NF-UB activation are not
fully known. Evidence is emerging, however, which indicates
that di¡erent agents may activate NF-UB through divergent
pathways. For instance IUBL has profound e¡ects on the ac-
tivation of NF-UB by LPS but not that by PMA or TNF [19].
Our results support the notion that di¡erent agents activate
NF-UB through di¡erent mechanisms. For instance, PI-3K
may be needed for NF-UB activation by LPS and PMA but
not for activation by other agents. That PI-3K is required for
NF-UB activation by LPS and PMA was also con¢rmed from
our independent studies in which we used cells from p85 (one
of the subunits of PI-3K) gene-knock out mice (Manna and
Aggarwal, manuscript in preparation). Recently, it was shown
that PI-3K is also needed for activation of NF-UB by IL-1
[12]. Wortmannin, however, like TNF, H2O2 and OA, had no
e¡ect on CD28-mediated NF-UB activation in T cells [13].
Whether wortmannin inhibits IL-1-induced NF-UB activation
through abrogation of IUBK degradation was not reported
[13]. Our results show that wortmannin inhibited NF-UB ac-
tivation by blocking the degradation of IUBK. How wortman-
nin blocks IUBK degradation is not clear. It may block phos-
phorylation and ubiquitination, an essential step that precedes
degradation [1], or another step upstream to it. Recently,
three di¡erent kinases have been implicated in IUBK phos-
phorylation, but whether those kinases are also needed for
NF-UB activation by LPS and PMA is not known [2]. We
found that wortmannin also blocked NF-UB-dependent re-
ported gene expression induced by PMA and LPS. This is
consistent with previous results on IL-1 [12]. Recently, the
role of PI-3K in NF-UB activation by bradykinin, pervana-
date and IL-1 was also reported [12,20^22]. TNF has been
found to activate PI-3K [23]. Recently several reports have
appeared which show that NF-UB activation requires a PI-
3K-Akt pathway [24^26]. Our results with LPS- and PMA-
induced NF-UB activation are consistent with these reports.
Our results also indicate that the activation of NF-UB by both
LPS and PMA is sensitive to H7, a speci¢c inhibitor of pro-
tein kinase C (PKC). That PKC could play a synergistic role
with PI-3K has been demonstrated [27]. Whether PKC di-
rectly activates PI-3K, however, is not well understood.
We found that besides NF-UB, PI-3K may also play an
important role in AP-1 activation by LPS and PMA. The
role of PI-3K in PMA-induced AP-1 activation is in agree-
ment with a recent report [11]. LPS is known to activate PI-
3K [28] and our results show that it is needed for AP-1 acti-
vation by LPS. Like NF-UB, PI-3K is needed for IL-1-induced
AP-1 activation [12]. In addition, EGF-induced AP-1 activa-
tion requires PI-3K [10]. The identity of the various intermedi-
ates involved in AP-1 activation are not fully known. Both
phospholipase D (PLD) and protein kinase C have roles in
CD3-mediated AP-1 activation in T cells [21]. Since PLD-in-
duced AP-1 activation is also blocked by wortmannin, it may
be that PI-3K is situated downstream of PLD [29]. Overall
our results demonstrate that PI-3K plays a critical role in the
activation of both NF-UB and AP-1 by LPS and PMA but
not by other agents. These studies provide an additional tar-
get to design anti-in£ammatory agents for diseases mediated
through NF-UB activation.
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